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ABSTRACT
Kentucky is a disparate state, ranking as one of the top states in incidence, prevalence,
and mortality for both opioid use disorders (OUD) and cancer. Due to the high volume of both
diseases in the state, there is a rising concern about the overlap of these two populations. Cancer
and its’ treatment are known to cause chronic pain, defined as daily pain lasting 3 months or
longer. Generally, chronic pain patients of any type are known to experience higher rates of
opioid misuse (21-28%) and opioid dependence (8-12%) than the general population (4.1%,
0.9% respectively). The risk of OUD must be considered when initiating long-term opioid
treatment for chronic pain, since a substance use disorder may result in poor pain control,
dysimmune effects, and tumor proliferative effects.
This program will utilize a transdisciplinary team approach to implement Screening,
Brief Intervention, and Referral to Treatment (SBIRT) at the University of Kentucky Markey
Cancer Center (UK MCC) in Lexington, KY to assess cancer survivors’ risk for developing
OUD, monitor opioid use during the first 12-months of survivorship, and refer patients to
alternative therapies to reduce reliance on opioids and improve pain management. The
implementation of the program will be evaluated with a process evaluation and an outcome
evaluation. Process evaluation metrics for the provider include: performance on trainings;
administration of assessments, opioid monitoring measures, and pain scales; and rate of opioid
prescriptions. Outcome evaluation metrics for the participant include: ability to manage pain;
satisfaction with pain treatment plans; rate of completed referrals to specialists; change in OUD
monitoring measure scores and number completed; and rate of opioid prescriptions. The
program will utilize existing resources through UK Healthcare, the MCC Affiliate Network, and
the MCC Research Network to implement the program to scale and disseminate findings across
the state and to stakeholders.
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TARGET POPULATION AND NEED
In the early 1990s, pharmaceutical companies claimed that opioids were not addictive
and assured medical providers and patients that they were safe to be prescribed with minimal
supervision. By 2015, the United States saw dramatic increases in prescription opioid abuse,
black market sales, and deaths, leading to intensive restrictions for opioid prescribing.1
Prescription opioids include oxycodone, hydrocodone, codeine, morphine, and many others,
which proved to be far more addictive than pharmaceutical companies originally claimed.2 The
restricted access to prescription opioids had unintended consequences: people who could no
longer have their opioid prescriptions filled began to transition to illegal opioids, like heroin, that
were often laced with highly-potent synthetic opioids, such as fentanyl. By 2017, overdose and
mortality rates skyrocketed and the U.S. Department of Health and Human Services department
declared the opioid epidemic as a national public health emergency. In 2018, an estimated 130
people died every day from opioid-related drug overdoses.1
While mortality rates are shocking, misuse of prescription opioids is substantially more
common. In 2018, the Substance Abuse and Mental Health Services Administration (SAMSHA)
found that across the United States, 9.6 million adults aged 18 or older misused prescription
opioid pain relievers in the past year, representing approximately 5.6% of young adults aged 1825 and 3.6% of adults aged 26 or older. An estimated 1.5 million adults misused prescription
pain relievers for the first time in 2018, meaning that approximately 4,400 adults misuse opioids
for the first time every day.3
In addition to the opioid epidemic, the United States has also experienced devastating
rates of cancer. As of 2017, cancer was the second leading cause of death with 599,108 cases,
following closely behind heart disease, with 647,457 cases.4 On a national level, as of January
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2019, there were approximately 16.9 million cancer survivors living in the United States,
representing 5.0% of the US population. The number of cancer survivors in the US is expected to
increase to 21.7 million people by 2029, and to 26.1 million people by 2040.5 The most common
cancer sites among survivors includes female breast (23%, 3.6 million), prostate (21%, 3.3
million), colorectal (9%, 1.5 million), gynecologic (8%, 1.3 million) and melanoma (8%, 1.2
million).6,7
Cancer and its’ treatment are known to cause chronic pain, defined as having pain every
day for more than 3 months.8 Cancer itself can cause pain in the body, typically from a tumor
pressing on nerves, bones, or organs. Cancer screening and treatments can also cause pain, such
as surgical pain from having a biopsy or tumor removed, or phantom pain after a body part has
been amputated. Chemotherapy can cause peripheral neuropathy, a set of painful symptoms such
as tingling or burning caused by damage to nerves, and gastrointestinal problems, such as mouth
and throat sores that make it painful to eat, drink, or talk. Lastly, radiation treatments also cause
pain, such as skin burns, scarring, and sores.9 Patients deserve to have their pain treated, and to
live a life as pain-free as possible.9
In light of the opioid epidemic, there has been investigation of opioid misuse in patients
with chronic pain in general, since the risk of substance use disorder must be considered when
initiating long-term opioid treatment.10 In 2012, the National Health Interview Survey (NHIS)
found that a total of 126 million adults (55.7%) reported some type of pain the last six months,
with nearly 40 million adults (17.6%) experience severe pain, and approximately 25.3 million
adults (11.2%) experience chronic pain.11 As seen in Table 1, in 2015, a systematic review of 38
studies found that the rates of opioid misuse in chronic pain patients averaged between 21%-28%
(range 95% CI: 13%-38%) and rates of substance use disorder to opioids averaged between 8%
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and 12% (range, 95% CI: 3%-17%).12,13 More information on how the Diagnostic Statistical
Manuals (DSM) have defined misuse versus dependence can be found in Appendix A.
Table 1. Comparison of Opioid Misuse/Dependence in Chronic Pain Patients and US
General Population
Chronic pain patients
General population

Opioid Misuse
21-28%
4.1%

Opioid Dependence Disorder
8-12%
0.9%

Kentucky is one of the United States’ leaders in the opioid epidemic,14 and will be the
catchment area for this proposal. According to 2019 Census data, there are approximately 4.5
million people living in the state. The state is 87.6% white alone, 8.4% Black or African
American alone, and 4% represent American Indian and Alaskan Natives, Asian, Native
Hawaiian and other islanders, and those with two or more races. 3.8% of the population identify
as Hispanic or Latino. The median household income from 2014-2018 was $48,392, with the per
capita income standing at $26,948 – nearly 17% of the state lives in poverty.15
In 2017, Kentucky providers wrote an average of 86.8 opioid prescriptions for every 100
persons as seen in Figure 1,13
compared to the
average US rate of 58.7
prescriptions.16 According to the
Centers for Disease Control
(CDC), in 2017 Kentucky reported
1,160 deaths related to opioids,
representing a mortality rate of 27.9 deaths per 100,000 persons, compared to the national
average of 14.6 deaths per 100,000 persons.16 Given the significantly higher rates of opioid
prescribing and opioid deaths in the state, it would be reasonable to consider that the rate of
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opioid misuse is likely higher than the national average.
As one of the most disparate states in the US, Kentucky has also experienced
disproportionate cancer burden. Kentucky has consistently ranked as one of the highest cancer
incidence and mortality rates of in the country, and currently holds the #1 spot with an average of
520.9 cases per 100,000 people annually between 2012-2016 (see Table 2).17,18 Since the
inception of the Kentucky Surveillance, Epidemiology, and End Results (SEER) Program of the
National Cancer Institute (NCI) in 1995 to the most recent data in 2017, there were 233,527
cases of cancer identified in Kentucky that are still living.19
Table 2. 2016 Age-Adjusted Cancer Rates:
Incidence, Mortality, and Survivorship in Kentucky and the United States
Kentucky
United States

Cancer Incidence
520.9 cases per 100,000 people
448.0 cases per 100,000 people

Cancer Mortality
234.9 cases per 100,000 people
189.8 cases per 100,000 people

Kentucky is well-positioned to be pioneers in ensuring that cancer survivors are having
their pain treated in the best way possible, with minimal risk of opioid misuse or developing an
opioid use disorder (OUD). A substance use disorder may result in poor pain control, and there
is evidence that opioids can cause dysimmune effects, such as increased inflammation, decreased
strength of the immune system and lower white blood cell counts, and tumor proliferative
effects, meaning an increase in the number of cells as a result of cell growth and cell
division.10,20 In 2019, the University of Kentucky Markey Cancer Center (UK MCC) conducted
a Community Needs Assessment (currently unpublished) among its patients and caregivers to
identify barriers to treatment. At the time of the submission of this grant, 13% of community
survey respondents and 9% of patient survey respondents reported that they used opioid
prescription medications just for the feeling, more than was prescribed, or were prescribed for
someone else on a monthly basis or more frequently.

5

It is important for healthcare providers to take a transdisciplinary team approach to
identify at-risk individuals and intervene with non-pharmacologic treatment methods to avoid
opioid misuse and dependence. There is a large evidence base showing that opioid continuing
education for healthcare professionals improves their ability to correctly prescribe & administer
opioids to patients, while reducing readmission for pain related issues and reducing stigma
surrounding those with opioid use disorder, and increasing providers participation in utilizing
prescription drug monitoring programs.21,22
A study published in 2017 found that cancer survivors are 1.22 times more likely to have
an active opioid prescription 10-years post-treatment.23 To stem the epidemic in prescription
opioid–related use among cancer survivors, the American Society of Clinical Oncology formed
an expert panel to conduct a systematic review of medical literature to develop evidence-based
guidelines on chronic pain management in cancer survivors. The guidelines included
recommendations such as screening for pain at every encounter, screening for opioid misuse,
utilizing physical functionality assessments to determine appropriate care, assessing the risks of
physical adverse effects of opioids used for pain management,24 and incorporating universal
precautions to minimize abuse, substance use disorder, and adverse events related to opioids.8 As
of 2020, there has not been a specific initiative to address opioid use in the cancer community at
Markey Cancer Center, ultimately leading to the development of this proposal.
The Substance Abuse and Mental Health Services Administration (SAMSHA) provides
funding for Screening, Brief Intervention, and Referral to Treatment (SBIRT) training and
implementation. SBIRT is the program that will be utilized in this proposal, defined by
SAMSHA as “an evidence-based practice used to identify, reduce, and prevent problematic use,
abuse, and dependence on alcohol and illicit drugs,” and is being expanded to include
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prescription drugs.25 Motivational interviewing is a cornerstone of SBIRT, and will be employed
to encourage patients to lessen their reliance on opioids and utilize alternative therapies to
improve their pain management.25 More information can be found in the Program Approach.
From 2013-2016, SAMHSA funded Medical Professional Training programs at
numerous locations across the United States, including Northern Kentucky University and for
University of Kentucky Research. Since 2003, SAMHSA has awarded 32 SBIRT grants to
states, territories and tribal organizations to enhance services for persons with, or at risk for,
substance use disorders. Despite the overwhelming rates of opioid dependence and overdose
death rates, Kentucky has not yet been awarded a state cooperative agreement for SBIRT.26
Regarding opioid monitoring resources currently available to the population, the
University of Kentucky Division of Community Medicine in the Department of Family and
Community Health established the Central Appalachia Inter-Professional Pain Education
Collaborative (CAIPEC). The goal of CAIPEC is to improve the delivery of chronic pain
management to the population of Central Appalachia through an evidence-based and interprofessional approach. CAIPEC was developed to work with practice-based research network
clinics and had three main aims: provide quality improvement methods for delivery of clinic
care, deliver statewide continuing education (CE) activities to address opioid use in patients with
chronic pain, and develop a multimodal mechanism to disseminate project results to clinics and
participating providers. The target audience of the program are healthcare professionals
including: Physicians, Advanced Practice Registered Nurses, Physicians Assistants, Massage
therapists, Physical therapists, and Behavioral Healthcare Professionals.27 CAIPEC is closely
tied to the UK Physical Therapy and the UK Interventional Pain Associates teams, providing
referrals to both when appropriate.
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CAIPEC also provides Chronic Pain Toolkit, a collection of resources and templates for
clinics to adapt based on their specific needs, designed to empower healthcare professionals to
make deliberate changes in their opiate prescribing practices.27 The toolkit is organized into 4
major sections: 1) Transforming Your Clinic Process, includes an implementation workbook for
the planning and implementation phases, such as worksheets, sample clinic workflows, etc.; 2)
Education Links, such as suggested guidelines, educational materials, and PowerPoint slide sets;
3) Resources, a repository of various instruments, such as physical functionality assessments,
screening tools, etc.; 4) Maintenance of Certification Part IV Resources, an opportunity for
providers to get credit for certification completion.
While the CAIPEC program offers a wealth of information and resources, it has not been
disseminated beyond the Family and Community Practice department. The original onset of the
program randomly selected eight clinics from the consortium to implement the program. This
program has shown to be effective, 28 and can likely be adapted to other clinic areas such as
cancer-related pain.
Other resources available UK Markey Cancer Center’s Integrative Medicine team,
offering services such as massage therapy, music therapy, acupuncture, yoga, Jin Shin Jyutsu and
others. Additionally, Markey hosts an exceptional Psych-Oncology team of ten social workers.
Their team focuses on: counseling patients and families after a diagnosis, throughout treatment
and beyond to help them manage the emotional and social challenges of living with and caring
for someone with a complex disease; teaching patients how to change behaviors (quitting
smoking, healthy lifestyle) to ensure the best possible outcome; connecting patients with the
services and resources they need to manage practical aspects of living with cancer, including
financial and nutrition counseling, transportation and housing assistance; and informing patients
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about resources available to them at Markey. They are a natural bridge between the initiatives of
the CAIPEC group and the aims of this proposal.
To address community outreach and dissemination, the SBIRT intervention could
potentially be expanded to the Markey Cancer Center Research Network (MCCRN) for further
evidence of validity and then implemented in all of the Markey Cancer Center Affiliate Network
(MCCAN) sites as a standard clinic protocol. MCCRN is comprised of 7 research sites who are
all part of the Markey Cancer Center Affiliate Network. MCCAN is comprised of 19 hospitals
across the state of Kentucky and encompasses the entire catchment area of MCC.
PROGRAM APPROACH
The main goal for Screening, Brief Intervention, Referral to Treatment (SBIRT), is to
improve community health by reducing the prevalence of adverse consequences of substance
misuse, including OUD, through early intervention and, when needed, referral to treatment.
SBIRT can be used as a preventative approach by targeting individuals with non-dependent
substance use, and is an effective strategy to intervene prior to the need for more extensive or
specialized treatment.29
To determine appropriate steps for cancer survivors and their pain management, our
proposal is to implement a clinic change process to include the Screening, Brief Intervention, and
Referral to Treatment intervention during cancer survivors’ follow-up appointments. SBIRT is
an evidence-based public health program sponsored by the US Substance Abuse and Mental
Health Services Administration, Center for Substance Abuse Treatment (SAMHSA, CSAT) to
“identify, reduce, and prevent problematic use, abuse, and dependence” on alcohol and tobacco,
and is being expanded to illicit and prescription drugs.25,30
SBIRT begins with a rapid assessment of substance use, then utilizes motivational
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interviewing techniques to assess a patient’s stage of change, as described in the Transtheoretical
Model of Change (pre-contemplation, contemplation, preparation, action, maintenance and
termination), and then performs a brief intervention.29,31 Motivational interviewing is a style of
counseling that guides participants to realize their personal goals, and helps to resolve
ambivalence that prevents them from reaching their goals by improving self-efficacy. The five
principles of motivational interviewing include: 1) Express empathy through reflective listening;
2) Develop discrepancy between clients' goals or values and their current behavior; 3) Avoid
argument and direct confrontation; 4) Adjust to client resistance rather than opposing it directly;
5) Support self-efficacy and optimism.32 On an interpersonal level of the Socio-Ecological
Model, the goal is to assist the patient in becoming more aware of their potentially problematic
behaviors, motivate them to change, and then refer them to a specialist. 33,34
The intervention will take place in three clinics at Markey Cancer Center that focus on
the following cancers: breast, prostate, and melanoma/skin. These particular cancer types were
chosen because they have over a 90% 5-year relative survival rate, and were three of the four
most common cancer sites treated at Markey in 2018.35,36 Due to the high patient volume in these
clinics, the investigative team suspects there will more likely be a subset of the population with
either a past history or future risk of opioid misuse or dependence. Clinic volume figures and
sample size calculation can be found in Appendix C. We will assess future risk of dependence by
having participants complete the Screener and Opioid Assessment for Patients with Pain
(SOAPP) Version 1.0-14Q, and utilize the Current Opioid Misuse Measure (COMM) during
follow-up appointments to assess misuse and determine need for a brief intervention.
Evidence Base of Screening, Brief Intervention, and Referral to Treatment (SBIRT)
In 1980, the World Health Organization made a call to the scientific world to improve
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treatment and diagnosis of people with hazardous alcohol use. The initial program of Screening
and Brief Intervention was developed at this time, and ultimately developing the Alcohol Use
Disorders Identification Test (AUDIT), which is now the most widely used evidence-based
alcohol screening test in the world. A decade later, the program was expanded to include the
Referral to Treatment component and has been applied in various settings across the globe.
SAMHSA funded three cross‐site evaluations to provide an independent, systematic examination
of its SBIRT programs to determine whether the grant program had achieved its intended
outcomes. The evaluation included two cohorts of grant recipients, totaling 11 programs, and
described in terms of the SBIRT service components, performance sites, providers, management
structure/activities and patient/client characteristics. In 2004, SAMHSA investigated the first
cohort of SBIRT grant awardees, with the second cohort’s evaluation taking place in 2009. As of
2017, the third cross-site evaluation was underway for the grant awardees in 2013 and 2014.
Overall, the evaluations found the program was effective in its’ intended outcomes, which was
consistent with previously published research.37
To further investigate the strength of the evidence-base of SBIRT, an overall review was
conducted, analyzing six meta-analyses of randomized clinical trials and one systematic review
on non-alcoholic alcohol drinkers. The review reported that 5 of 7 studies found a moderate
decrease in consumption, and 4 of 7 studies experienced a significant decrease in the number of
participants who continued to use alcohol. The review also determined that a brief 15-minute
intervention at multiple points of manifests lasting effects that persist for at least 6 months.38
This supports SBIRT’s claim that the program is effective in preventing problematic use, and is
not only for those who have already developed a substance use disorder.
SBIRT is effective in a wide range of settings including emergency rooms, primary care
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clinics, and community settings. Additionally, the SBIRT framework is valid to use for
adolescents, adults, and seniors. The screening component has found to be effective in a variety
of modalities including telephone, paper, online, and physician administered. The flexibility and
validity of this framework for tobacco and alcohol use in various settings, populations, and
modalities gives strong support for the success of employing this method for prescription
medications, such as opioids.34 Additionally, motivational interviewing has been found to be
effective in chronic pain populations wishing to taper their opioid dose.39
In March of 2019, several medical doctors at Yale University conducted a randomized
controlled trial using an adapted SBIRT-Pain Module (SBIRT-PM) that they had created to
effectively screen for substance use disorders in veterans with chronic pain stemming from
musculoskeletal disorders. The trial had three arms at a 2:1:1 randomization ratio: SBIRT-PM
with counselling, Pain Module counseling only, or standard of care without counselling. Those
who were randomized to the counselling conditions were significantly more likely to fulfill
service referrals and make changes to their pain management plan. Participants in SBIRT-PM
were significantly less likely to use substances over time (β = –0.13, P = 0.015, d = –0.84). The
standard of care group were more likely to withdrawal from the study at week 12 (32% vs 12%
and 11%, respectively; P < 0.05). Ultimately, SBIRT-PM showed promise as a way to engage
veterans in pain treatment and reduce substance use, and provides evidence that SBIRT can
effectively be used in a chronic pain population.40
Adaptations
SBIRT has been shown to be effective in a variety of settings but have primarily focused
on tobacco and alcohol use, and has limited its focus to non-cancer pain populations. The first
major adaptation in this intervention is using SBIRT in a cancer survivorship population with
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cancer-related pain, who may also experience chronic pain. The second major adaptation to this
intervention is using SBIRT for prescription opioid dependence. Currently, the effectiveness of
SBIRT in cancer pain populations or in populations with prescription opioid dependence are
unknown. Minor adaptations include using screening tools that will be used to assess need for
risk monitoring and for assessment of opioid misuse, abuse, and dependence. The major
adaptations of this intervention are essential to addressing opioid dependence in cancer
survivors. In light of the opioid epidemic, it is now more important than ever to ensure that
oncologists are confident in their opioid prescribing practices for their patients, and that patients
are satisfied with their pain management treatment course. Anecdotal evidence shows that
providers are already using SBIRT and motivational interviewing techniques to address opioid
use in cancer patients. To date, there have not been any studies targeting this vulnerable
population specifically with the SBIRT methodology.
Education, Stigma Reduction, Claims
There are major challenges regarding stigma reduction towards people who have cancer,
people who receive opioid prescriptions, and those who have or are at risk of developing an
OUD. It is important to remember that the goal of this program is to improve the cancer
survivorship experience by identifying whether individual patients are best served by opioids for
managing their pain; not to unnecessarily take away their medications. There are some cancer
survivors who will have severe chronic pain for the rest of their lives and may need to be on
some level of opioids during that time.41,42 Cancer patients experience substantial pain from their
treatments, and deserve to have that pain treated without feeling as though their provider or clinic
staff is judging them for continuing to take opioid prescriptions. On the other side of the lens,
providers understand how painful cancer can be, so they may not be concerned about a cancer
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patient’s opioid prescriptions, and be unaware of whether opioids may be inciting more harm
than help.
There is strong evidence that educational anti-stigma interventions are successful in
reducing stigma.21,22,43 Our education plans for the clinic providers and staff regarding cancer
pain will include the full spectrum of cancer treatment side effects, their correlation with pain,
and appropriate pain management plans. To reduce stigma related to opioids, our education plans
will focus on the neurological and physiological changes that happen after taking opioids for an
extended period of time. This is essential for clinic staff to understand the underlying
mechanisms that drive resistance to opioid reduction and cessation. By educating the clinic staff
in this aspect, it will help them to understand from a biological level what is happening with their
patients, and that it is not merely a moral failing or lack of motivation. Lastly, we will build
providers confidence in their ability to prescribe the appropriate amount of opioids to their
patients without needing to worry about contributing to the opioid epidemic.
Sustainability
This intervention is intended to be a clinic process change. We are intentionally designing
this project to have the clinic staff provide and score the initial risk monitoring tool (SOAPP) to
the participant, and then informing the provider of their score and whether they qualify for a
brief intervention, rather than assigning these tasks to behavioral research associates whom will
no longer be involved in the process after the grant ends. While there are still areas that can fail
post-project period, our intention is that the screening mechanisms will become standard
operating procedures embedded into the clinic workflow beyond the funding cycle of the grant.
Our activities of providing the training to conduct the FMEA, intensive training with PDSAcycle worksheets, and implementing the practice management specialist support this aim.
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Additionally, the clinic champions will also receive motivational interviewing training to help
them navigate resistance within the clinic staff and hold providers accountable to their training.
If our program is found to be implemented appropriately, as determined by the process
evaluation and the outcome evaluation, the data from this project will allow the institution to
secure funding from SAMSHA to provide an expanded, formal SBIRT training program for
providers. Securing additional funding will further disseminate SBIRT implementation,
resulting in an overall cultural change in the institution. We will communicate our study results
via the MCCAN and MCCRN networks, UK Healthcare, and to the CAG, partners, and
stakeholders through roundtable discussions, presentations, conference attendance, and others as
deemed appropriate.
Inclusivity and Appropriateness for the Population
To ensure that all program materials are medically accurate, inclusive, and culturally and
linguistically appropriate, we will use nationally recognized evidence-based guidelines and
educational materials from the CAIPEC resources. We will submit materials that will be viewed
by our participants to the Human Development Institute (HDI) at the University of Kentucky to
assist in identifying any needed modifications. The Human Development Institute’s website
states that their mission is, “To promote the inclusion, independence, and contributions of people
with disabilities and their families throughout the lifespan. We achieve our mission through
education, research and evaluation, information sharing, leadership, and advocacy across
Kentucky and the nation.”44 As a final reviewing team, we will employ our Community
Advisory Group to review all materials to ensure that our material messages will be received in
the way that they are intended.
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To address any concerns the participants may have during their participation, we will
supply several avenues for them to submit claims. The University of Kentucky Office of
Research Integrity website states that, “It is IRB policy that a safe confidential, and reliable
channel for current, prospective, or past research participants, their representatives or others, is
provided that permits them to discuss problems, concerns, and questions; obtain information; or
offer input with an informed individual who is unaffiliated with the specific research protocol.
Each IRB approved informed consent document includes the ORI Research Compliance
Officer's toll-free phone number (1-866-400-9428) as a subject's primary contact point for this
purpose.”45 Additionally, they will be given contact information for the primary investigators
and research coordinator to submit concerns and claims. Lastly, the research staff will directly
address the potential for these issues by directly asking participants at the end of their
participation whether they had any concerns about their participation.
Recruitment and Retention
For an effective intervention, we will need to have a recruitment and retention plan for
both the clinics and the patient participants. Clinic recruitment and retention is essential to the
success of this intervention and requires a champion to ensure that the intervention is maintained
in the workflow. Potential clinic champions and physicians have been recruited by utilizing a
mutual acquaintance in the cancer center to establish an interpersonal relationship. The research
team met with each clinic team to explain the purpose of the study and why their particular clinic
was chosen as a potential participant. Clinic champions and physicians will be monetarily
compensated for their time at an appropriate rate to ensure that they are satisfied with the
additional steps in the clinic workflow. To encourage clinic retention, the clinics will have
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monthly challenge rewards for those who completed the most screenings and had the most
successfully completed referrals.
To recruit participants, study personnel will conduct the screening of potential
participants, and inform the clinic staff of which people should be approached. The clinic staff
will insert the research study consent form into their intake packet, to be reviewed while they are
waiting for their appointment. Study personnel will review the study protocol, including referral
to treatment options, and consent form with the patient. If willing to participate, the study
personnel will obtain a signed informed consent and provide a copy to the participant.
Compensation for the participants’ time will include an initial $5 for completing the initial risk
monitoring survey, provided to the participants and scored by the clinic staff, who will then
inform both the study personnel and clinic provider on whether they are mild, moderate, or
severe risk for dependence. To retain participants, the follow-up surveys will be completed
during their regularly scheduled follow-up appointments. To compensate for their time,
participants will receive $5 for each follow-up survey completed, totaling $15. If the participant
completes all three follow-up surveys, the will receive an additional $15 at the completion of the
study participation. This type of payment schedule is an acceptable standard in substance use
populations for maximum retention, and the payment amounts are deemed low enough to prevent
unintended coercion.
Since our target population is very specific and medically frail, we expect to have some
difficulty with recruitment into the study. To assist in determining what changes need to be made
in our recruitment strategy, we will ask eligible participants why they declined or agreed to
participate. We will provide a set of responses in checklist format with an option for “other” to
reduce burden on those who agree to answer. The responses will be determined by the focus
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group prior to the beginning of the study and modified based on frequent fill-in responses from
the “other” category.
Monitoring and Fidelity
Please see the Process Evaluation section of this proposal provides detailed information
on how the sites will be monitored. To ensure fidelity and loyalty to the proposal, we are
providing a $20,000 clinic stipend to increase buy-in from the staff by providing protected time
for them to conduct the study. We will also identify a champion in each of the three clinics who
will enthusiastically commit to the protocol and purpose of the study.
A 6-month readiness period for the implementation of the study will be employed to
allow for an adjustment period. The readiness period will give the clinics an opportunity to get
comfortable with motivational interviewing techniques before deploying in the research setting.
During the first three months of the readiness period, providers and clinic champions will be
trained in motivational interviewing techniques using resources provided by SAMSHA. “A Tour
Motivational Interviewing: An Interprofessional Road Map for Behavior Change” is a free, selfpaced online course provided by SAMSHA, and was prepared by the University of Missouri
Kansas City School of Nursing and Health Studies’ Mid-America Addiction Technology
Transfer Center.46 Additionally, they will be provided with an "MI Reminder Card (Am I Doing
This Right?),” a pocket card reference guide to take with them in the clinic. The 11 questions on
this card assist in building self-awareness about the interventionists’ attitudes, thoughts, and
communication style as they work.46 The providers and champions will give a mock motivational
interviewing intervention with a non-trained clinic staff worker each month. Both the clinic staff
worker and the trainee will be given a case scenario for the ‘patient’ to act out. The mock
intervention will be video recorded in order to reduce the Hawthorne Effect, and then observed

18

and scored by the Oncology Social Work trainer, who will grade the interaction based on the
training manual standards. The trainee will be asked to view their interaction and grade
themselves, then a meeting will take place to identify areas of improvement and conduct
refresher training. Please refer to the Process Evaluation section for metrics that will be
measured.
Challenges and Risks
Clinic-based research studies, such as this proposal, face unique challenges due to the
setting. The most difficult challenge is that medical clinics are already exceptionally busy,
severely limiting available time to identify eligible participants and conduct research. We will
employ a Practice Management Specialist to find time savings in the clinic, as well as a Clinic
Task Force to help ensure that the participant and provider have enough time in the clinic to
complete the study materials, and maintain the integrity of the protocol as written within the
clinic workflow. We will also provide a clinic stipend as an incentive for the clinics to assist in
holding themselves accountable to maintain the research project. Buy-in from providers and
clinic staff is essential to the success of this project. Another major challenge is that our
providers cannot be blinded to the intervention, meaning that they may unintentionally bias
results. Additionally, the providers may begin using the techniques and screening measures
they’ve acquired during the study when interacting with other patients who are not enrolled.
The risks for patients to participate in this study are minimal and do not exceed the risks
encountered in everyday life. Some questions on the study measures may be of sensitive nature
and uncomfortable for some participants to answer. All participant contribution is voluntary,
participants are allowed to skip any questions that they do not want to answer and can
discontinue their participation at any time. Patient materials will be de-identified and coded with
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a unique participant code and will follow the UK Standard Operating Procedures to maintain
HIPAA compliance and Good Clinical Practice guidelines.
PERFORMANCE MEASURES AND EVALUATION
This proposal will use a stepped-wedge study design, also known as a phased
implementation, with each clinic serving as its own control. To measure whether the
intervention is effective and not due to external factors, we will compare baseline counts for the
outcome measures versus post-implementation counts. We will “Go-Live” in Clinic 1 during
Year 1, month 7; Clinic 2 in month 9; and Clinic 3 in month 11. This will provide two months of
data collection in each clinic, and an opportunity to improve the intervention before deploying in
the next clinic. This timeframe also allows to have two months of implementation in Clinic 3
before the beginning of Year 2 of the project. This design is ideal from an ethical standpoint: this
is a high-risk population and it is imperative that all eligible participants receive the intervention.
More information on Study Design, Eligibility, and Sample Size can be found in Appendix C.
The first measure we will administer to participants is the Screener and Opioid
Assessment for Patients with Pain (SOAPP) Version 1.0-14Q and is meant to be completed
before a patient is placed on a long-term opioid therapy, when a pain management plan is
established.47 See Appendix D for full instrument, and Table 3 for cutoff score information. This
tool is designed to assist clinicians in determining how much monitoring a patient on long-term
opioid therapy will likely require and takes approximately 8 minutes to complete. It is essential
to ensure that cancer survivors have adequate chronic pain management because all people
deserve to be as pain-free as possible. In light of the opioid crisis, many practitioners are hesitant
to prescribe opioids,42 and this tool helps to clarify concerns.
One important, yet often overlooked, aspect of the COMM tool is that it addresses family
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history of substance abuse and whether the patient has ever had their medications lost or stolen,
which can be an indicator to educate patients on proper opioid storage at home.48 This item is
imperative because in Kentucky, of those who use prescription opioids non-medically for more
than 200 days per year, 27% use their own prescriptions; 26% are given them by friends or
relatives; 23% buy opioids from friends or relatives; and only 15% buy from a drug dealer.49
Since the prescribing rates in the south eastern and south western parts of KY are much higher
than the central part of the state, our research team and providers will need to be proactive in
addressing shared prescriptions. If a participant from a high-risk area indicates that they have
had prescriptions lost or stolen, or friends or family with substance abuse disorders, our
providers will take special care to address this during the motivational interviewing intervention.
Table 3. SOAPP and COMM Cutoff Scores
Sensitivity
SOAPP
Score 7 or above .91
Score 8 or above .86
Score 9 or above .77
COMM
Score 9 or above .77

Specificity

Positive
Predictive
Value

Negative
Predictive
Value

Positive
Likelihood
Ratio

Negative
Likelihood
Ratio

.69

.71

.90

2.92

.13

.73
.80

.75
.77

.86
.80

3.19
3.90

.19
.28

.66

.66

.95

2.26

.35

The second measure we will administer to participants is the Current Opioid Misuse

Measure (COMM), a 17-item self-report instrument designed to monitor a chronic pain patient's
use of opioids and assess misuse by asking about social, emotional, and functional problems and
behaviors related to prescription medication misuse.50 See Appendix E for full instrument. The
COMM will be administered during the 3 month, 6 month and 12 month follow-up
appointments. Follow-up timelines vary dramatically depending on the type of cancer, location,
and treatments (radiation, chemotherapy, surgery), however it is standard at minimum to have a
3, 6, and 12 month follow-up appointment. Regarding the construct validity of the instrument,
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Meltzer et al. found higher COMM scores in patients with chronic pain who had a prescription
drug use disorder than in those who did not have the disorder.51 Table 4 below shows the
psychometric properties associated with our validated measures, including the Opioid Therapy
Provider Survey (OTS), which is used in the Process Evaluation.

Table 4. Validity of Measures
Construct
Psychometric Properties
Prediction of
Need for
Opioid Risk
Monitoring

Opioid Misuse
Assessment

Pain Levels

Provider
confidence in
prescribing
opioids

Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1.0-14Q.
The 14-item survey is scored on a 5-point Likert scale. Chronbach’s alpha was
calculated for initial SOAPP results (N=175) and for follow-up retest (N=95),
achieving a=0.74 for both samples.47 Negative Predictive Value for a cutoff score of 7
is .90; score of 8 is 0.86, and score of 9 is 0.80. Despite its’ intention to capture as
many people as possible, leading to many false positives, a person with a positive
SOAPP score at the cutoff of 7 is 2.94 times as likely to be someone who is actually at
high risk; scores of 8 are 3.19 times as likely; scores of 9 are 3.90 times as likely.
Current Opioid Misuse Measure (COMM). This tool is intentionally designed to overidentify misuse, rather than failing to identify those at high risk (PPV = 0.66, NPV =
0.95). A study published in the Clinical Journal of Pain examined the validity and
reliability of the COMM against the Aberrant Drug Behavior Index (ADBI), finding
the internal consistency for cross validation to be excellent with a = 0.83, compared to
a = 0.86 in the original study. The receiver operating characteristic curve (ROC)
analysis yielded an area under the ROC (AUC) of 0.79 (Standard error = .031; 95% CI:
.74 to 86; p < .001).50
FACES Pain Scale. A study comparing four pain scales in children ages 3-18 found the
FACES Pain Scale to be valid and reliable: a = .60, r = .74. There were no significant
differences in validity or reliability across all four measures.
Opioid Therapy Provider Survey (OTS). The 10-item survey is scored on a 5-point
Likert scale, where 1= strongly agree and 5= strongly disagree.52 All items were based
on an extensive literature review, then developed through consensus among researchers
with over 20 years averaged experience with chronic pain patients. Content validity
was initially established through item examination for missing data and respondent
comments and reliability was judged to be suitable (Cronbach's alpha = 0.28).53

Both the SOAPP and COMM measures take less than 10-minutes to complete and are selfreported, making it practical for the patient to complete during their clinic visits without
significant disruption of the clinic workflow. Additionally, both measures use the same scoring
methods, by summing the individual question scores to calculate the overall total score. Using
similar scoring mechanisms will reduce the need for additional training.
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Patient satisfaction and ability to manage pain will be measured by using a self-report
survey at each encounter, as seen in Tables 5. These items will be developed with assistance
from the Behavioral Research Assistant.
Table 5. Patient Perspective Measures
Property
Patient Satisfaction
Pain Management

Verbiage
“How satisfied are you with
your pain treatment?”
“How well are you able to
manage your pain?”

Scoring
5-point Likert scale (1 = Extremely
Dissatisfied to 5 = Extremely Satisfied)
5-point Likert scale (1 = Extremely
Dissatisfied to 5 = Extremely Satisfied)

To measure pain levels, we will use the Wong-Baker FACES Pain Rating Scale (0 = No
Hurt, 10 = Hurts Worst) as
seen in Figure 2.54
Physical functionality will
be measured using
assessments provided in
the CAIPEC toolkit.

Figure 2. Wong Baker FACES Pain Rating Scale54

Process Evaluation
The process evaluation for this program will be closely tied with the project management
plan to ensure that we are implementing the project according to the project schedule and
reaching the goals of the program. A Failure Modes and Effects Analysis (FMEA) will be
conducted several times during the project by the Clinic Task Force, as seen in the Gantt Chart,
specifically during the last 3 months of the readiness period (Year 1 Q2), during the first 6
months post-Go-Live (Year 1 Q3, Q4) and then at Year 2 Q1 and Q4. To conduct the FMEA, we
will assess the following: 1) Steps in the process 2) Failure Modes (What could go wrong?) 3)
Failure Causes (Why would the failure happen?) 4) Failure Effects (What would be the

23

consequences of each failure?).55 We will use a team approach to modify the protocol to address
the concerns. During the lifetime of the project, we will track the identified FMEA aspects
during the project with our PDSA cycle worksheets. Table 6 below outlines the process
evaluation metrics that will measured to ensure proper provider education to support successful
implementation and execution.
Table 6. Process Evaluation Metrics for Providers

1) Quiz scores on SBIRT and educational trainings including:
a. Provider knowledge of guidelines for cancer pain patients and opioid prescribing
b. Knowledge of palliative care alternative therapies for appropriate types of pain
c. Confidence in prescribing opioids (OTS Survey)
2) Motivational interviewing performance
3) Number of physical functionality assessments completed
4) Number of opioid monitoring measures given
5) The number of referrals given for alternative therapies
6) Number of FACES pain scales administered
7) Rate of opioid prescriptions

The metrics for rate of opioids prescribed and number of referrals given and filled will be
extracted from the Electronic Health Record. Physical functionality and FACES scale numbers
will be inserted into the Electronic Health Record as well to improve sustainability and
adherence to the protocol. To measure the providers’ knowledge of guidelines for cancer pain
patients and knowledge of alternative therapies for appropriate types of pain available at UK, we
will conduct a pre-test prior to education and training during the readiness period. Since
availability of therapies are location-specific, we will need to modify existing measures provided
in the CAIPEC toolkit.
To identify key successes, challenges, and lessons learned, we will conduct key
informant interviews every month with the providers, clinic staff, and project staff. The topics of
conversation in the interviews will begin with reviewing the PDSA cycle worksheets and how
they have aligned with the pre-project FMEA analysis. We will also review metrics that we have
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collected during the project, specifically the recruitment strategies, recruitment numbers, number
of referrals given and completed, counts of major and minor protocol deviations, patient
satisfaction, etc. The interviews will allow the team to provide their input as executors of the
protocol and study impact, while providing confidentiality. We have elected key informant
interviews rather than focus groups to offset group-think about how well the intervention is
working. Additionally, key informant interviews provide the opportunity to receive more
detailed feedback about how the providers, clinic staff, and other project staff are performing and
interacting with participants without risking fear of retaliation.
Outcome Evaluation
To assess the impact of the SBIRT intervention and determine the extent to which the
outcome goals were met by the program and not due to chance or external factors, we will
compare baseline metrics to post-implementation metrics. Output metrics for the participant are
listed in Table 7.
Table 7. Outcome Metrics for Participants

1) Satisfaction with pain treatment
2) Ability to manage pain
3) Scores on opioid monitoring measures (SOAPP and COMM scales)
4) Number of opioid monitoring measures completed
5) Number of referrals to palliative care or alternative therapies completed by the patient.
6) Rate of opioid prescriptions

CAPACITY OF APPLICANT ORGANIZATION
The University of Kentucky is categorized as a Research Intensive Institution that has
extensive experience in implementing evidence-based programs on a large scale, as well as
implementing projects in the communities. Research and academic activity at the University of
Kentucky (UK) spans all 16 colleges, the Graduate School (including the James W. Martin
School of Public Policy and Administration and the Patterson School of Diplomacy and
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International Commerce), some 80 multidisciplinary research centers, and 30 core research
facilities. UK is one of 115 private and public universities in the country to be classified by the
Carnegie Foundation for the Advancement of Teaching among Doctoral Universities: Very High
Research Activity (R1) in 2018. R1 universities represent 2.5% of all institutions in the
classification system. UK faculty, staff, and students brought in more than $417.1 million in new
sponsored project awards in FY 2019. Of that total, UK was awarded $241.8 million in grants
and contracts from federal agencies.
In regards to substance misuse and abuse, UK is home to the Center for Drug Abuse
Research, which facilitates the largest research grant ever received by the University of
Kentucky, NIH’s HEALing (Helping End Addiction Long Term) Communities Study. The
HEALing Communities Study is a four-year, $87 million study aimed at reducing opioid
overdose deaths by 40 percent, and was developed by researchers from UK spanning six
colleges, in partnership with state leaders. As one of four sites nationwide, UK and the
Commonwealth of Kentucky will address the opioid epidemic in a randomized study that
includes 16 Kentucky counties acutely impacted by opioid abuse. The study will leverage
existing resources and initiatives, in partnership with communities, to implement strategies and
set evidence-based standards that will become a national model for fighting the opioid epidemic.
As the only NCI-designated cancer center in Kentucky, MCC's mission is to reduce
cancer mortality through a comprehensive program of cancer research, treatment, education, and
community engagement with a particular focus on the underserved Appalachian population of
eastern Kentucky. Since UK MCC is so robust, it hosts its’ own business office to manage
financial resources, interfacing closely with the main campus Accounts Payable and Payroll
departments. According to the 2018 Annual Report, MCC is driven by 235 research projects
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representing more than $41 million in research, with 2.7 million dedicated to education and
research training. The MCC treats nearly 3,400 new cancer patients and over 8,000 returning
cancer patients and survivors annually at the Chandler Medical Center.36
MCC has a substantial community partnerships across the state of Kentucky MCC’s
MCCAN and MCCRN sites extend into Appalachia and surrounding regions at 22 separate
facilities with a shared vision of increased access and delivery of high-quality cancer care, and
clinical trials. A new collaboration, UK Markey Cancer Center at Lexington Clinic will enhance
and expand outpatient cancer care throughout Central Kentucky.
The University of Kentucky is home to extensive quality improvement initiatives,
ranging from clinical care to research to administration. UK HealthCare delivers high-quality
continuing professional development activities to physicians, pharmacists, and other health care
professionals via the CECentral platform, which functions as a full-service continuing education
(CE) solution for healthcare professionals. To manage staff performance, UK uses enterprise
services for annual performance reviews, time entry, and paid leave.
The University of Kentucky is committed to a diverse and inclusive workforce that
strives to foster a community where people regardless of sex, race, ethnicity, religion, age,
ability, sexual orientation, or gender identity, can feel secure and welcome. In the interest of
maintaining a safe and healthy environment for our students, employees, patients and visitors the
University of Kentucky is a Tobacco & Drug Free campus. As an Equal Opportunity Employer,
we strongly encourage veterans, individuals with disabilities, women, and all minorities to
consider our employment opportunities.
PROJECT MANAGEMENT
The project management plan below describes how the project will be implemented,
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managed, and monitored. See Appendix F for the Logic Model and Appendix G for the Gantt
Chart, detailing activities during the 3 year project period, including plans for FMEA analysis
and PDSA-cycle worksheets. Once the project reaches the “Go-Live” stage, we will use “PlanDo-Study-Act” (PDSA) worksheets to delineate areas of improvement for our program, found in
Appendix H. We will determine our initial approach and set a goal number for the appropriate
activities, such as participant accrual. During the initial 3 months post-Go-Live, we will ‘study’
the approach and the accrued metrics on a bi-weekly basis before making minor changes for the
second round of the PDSA cycle. A bi-weekly cycle schedule is ideal, since it is long enough to
allow enough time for changes to gain traction but short enough to prevent major issues to go
unnoticed. During months 5-12, we will continually assess the study progress to address
significant changes that need to be made, such as changes in clinic workflow, refresher training
for project staff, changes in data collection or management processes, participant recruitment and
attrition, and others. By the end of year 1, we expect to have solidified and stabilized all aspects
of the protocol to run smoothly through years 2 and 3. We plan to conduct interim statistical
analysis every 6 months to monitor impact.
Project Management: Team Responsibilities
See Appendix I for the Organizational Chart, outlining personnel reporting lines.
Table 8. Project Management: Team Responsibilities
Title
Primary
Investigator

Project
Director

Responsibilities
1) Provide consultation to clinics and act as final authority on workflow changes
2) Review high-level progress reports of the project to ensure milestones are being
met in accordance with the funding sponsor’s guidelines
3) Review potential participants’ screening files and approve enrollment
4) Assist in hiring and termination of key staff
5) Act as the emergency contact for Adverse Events and Serious Adverse Events.
6) Disseminate findings to CAG, Partners, and Stakeholders.
1) Develop, monitor, and make any necessary changes to the research protocol,
budget, process evaluation, staff scheduling, IRB continuation review
submissions, research participant payments, and other administrative activities as
deemed necessary.
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Clinic
Providers

Oncology
Social Workers

Behavioral
Research
Associates

Biostatistician

Practice
Management
Specialist
Clinic Task
Force

2) Identify and interview key project staff. Supervise all project staff. Ensure proper
trainings have been completed by all research staff, clinic personnel, and clinic
providers. Assess professional development needs; provide at minimum annual
professional development opportunities for research staff and semi-annual
opportunities as deemed necessary.
3) Engage the Community Advisory Group
4) Report Adverse Events and Serious Adverse Events to the appropriate authorities
on the appropriate timelines.
1) Central point of contact between participants and research team.
2) Conduct motivational interviewing techniques to improve likelihood that a
participant will agree to reducing opioid prescriptions and follow through with
referrals.
3) Provide referrals to alternative therapies for participants.
4) Provide brief report of interactions with participants to clinic staff, to be passed
off to Behavioral Research Associates for documentation.
1) Provide sensitivity and motivational interviewing trainings to clinic providers.
Track education and trainings for all clinic personnel and report to Project
Director.
2) Assist in patient navigation to schedule their referral appointments, arranging
transportation to/from the clinics, etc.
3) Coordinate with Behavioral Research Associates to ensure all participant materials
and data are available and entered according to project timelines.
4) Act as mediator for tension between providers, clinic staff, and participants.
1) Reviewing Electronic Medical Record data to identify eligible patients for
recruitment
2) Approaching patients in the clinic to recruit into the study, completed all screening
and consent procedures. Ensure protocol materials have been complete and
returned by clinic staff.
3) Provide participant payments.
4) Review all data collection and ensure procedures have been followed according to
Good Clinical Practice Guidelines.
5) Enter paper-based survey data. Conduct minor data management as needed.
6) Provide administrative services such as putting together materials for participant
screening files, creating participant calendar schedules, tracking demographic
metrics for IRB continuation review reporting, etc.
1) Develop study design
2) Conduct sample size and power calculations
3) Conduct preliminary, intermediary, and final data analysis
4) Conduct major data management as needed
5) Provide data interpretation summaries and figures for presentations, publications,
future grant proposals, etc.
1) Identify places in clinic workflow to find time-savings in order to insert research
protocol without increasing required clinic time for the study.
2) Conduct the Failure Modes and Effects Analysis.
1) Ensure proper implementation of the study into the clinic workflow to increase
sustainability after the project grant funding ends.
2) Track progress of Failure Modes Effects Analysis and Plan, Do, Study, Act
worksheets.
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Clinic Staff

1) Coordinate with the behavioral research associates to ensure that identified
participants who are potentially eligible for the study are screened, and if eligible,
consented.
2) Distributed the SOAPP and COMM scales to the participants.
3) Score SOAPP and COMM scales, communicate to provider whether a brief
intervention or referral to treatment is needed.
4) Provide completed SOAPP and COMM scales to the Behavioral Research
Associates, along with all reports from the provider.
5) Contact Oncology Social Work team to assist with patient navigation.

PARTNERSHIPS AND COLLABORATION
Our stakeholders and partners are entities that are imperative to the successful
implementation of the proposed project. We have identified groups from a national, state-wide,
and the local community level to ensure comprehensive representation, seen in Table 9. We have
obtained letters of support for all entities listed below. Effective two-way communication with
stakeholders and partners is essential to the success of this project. Our Primary Investigator and
Project Director will be the central points of contact for all communications. We will disseminate
a quarterly newsletter to local entities, host bi-annual meetings with local and state entities, and
provide a bi-annual report to local, state, and national level groups.
Table 9. Stakeholders and Community Partnerships
Entity
Level
Role
American College of Surgeons Commission on Cancer

National

American Society of Clinical
Oncology

National

US Department of Health and Human
Services

National

Kentucky Injury Prevention and
Research Center (KIPRC)

State

A consortium of professional organizations
dedicated to improving survival and quality of life
for cancer patients through standard setting, which
promotes cancer prevention, research, education,
and monitoring of comprehensive quality care.
Diverse network of nearly 45,000 oncology
professionals dedicated to providing the highestquality resources in education, policy, the
pioneering of clinical research, and advancing
cancer care.
The largest biomedical research agencies in the
world. Made of 27 Institutes and Centers,
including the NIH, NIDA, NCI, and SAMHSA
Partnership between UK and Kentucky Dept. for
Public Health. Works to reduce injury through
education, policy initiatives, public health
programming, surveillance, risk factor analysis,
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direct interventions, and evaluation. Hosts
findhelpnowky.org.
Controlled substance prescription monitoring
system, tracks prescriptions per person to assist
medical personnel in decision-making.
Performs essential functions such as providing
police protection, administrating health and
welfare services, keeping records, establishing
policies and laws.
Provide medical services to Kentucky residents.
Stakeholders who have a vested interest in the
opioid epidemic, cancer treatment, and quality
improvement initiatives.

Kentucky All Schedule Prescription
Electronic Reporting (KASPER)

State

Lexington Fayette Urban County
Government and Health Department

Local

Local Lexington Hospitals: St. Joseph
Health, Baptist Health, Lexington VA
Medical Center, The Ridge Behavioral
Health System, Eastern State Hospital

Local

UK Office of the Vice President for
Research

Research Major research entity at UK; provides oversight
and guidance of 13 multidisciplinary research
centers, including MCC and CCTS
Research Conducts research into the biological,
psychological, sociopolitical, and clinical aspects
of substance abuse and related behavior. Provides
consultations to public agencies and state and local
government
Clinical Provide medical services to Kentucky residents,
&
ensuring best practices are being followed. Major
Research drivers for implementation of new research
Clinical findings. These entities are directly involved in this
Clinical grant proposal and will be represented when
Clinical disseminating findings to other groups.

UK Center for Drug Abuse Research

UK College of Medicine
UK Healthcare
UK Interventional Pain Associates
UK Healthcare Palliative Care Team

Community Advisory Group
We will establish a Community Advisory Group specifically regarding opioid misuse in
cancer survivors. The Primary Investigator of this project has identified 7 main areas to obtain
representation, and will host bi-annual meetings to discuss barriers to implementation, challenges
with clinic work flow, recruitment and retention, and other challenges in addition to the
communications with stakeholders and partners mentioned above. To recruit these individuals,
the Primary Investigator will reach out to the organizations by prioritizing those of which they
already have established connections. For those that do not have an established network, the PI
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will directly contact the organizations to request a meeting consultation. All individuals will be
compensated monetarily for their time on the CAG. The Community Advisory Group will
ideally be comprised of individuals from the organizations in Table 10.
Table 10. Community Advisory Group
Entity
Personnel
Markey Cancer Center Affiliate
Network
Markey Cancer Center Patient
Advisory Group
UK Central Appalachian InterProfessional Educational
Collaborative (CAIPEC)
UK Helping to End Addiction
Long-term (HEAL) Initiative

John Lennon, Director

Voices of Hope

Paul McCartney, Co-founder

Bluegrass Care Navigators
Cardinal Hill Rehabilitation
Center,
Kentucky Cabinet for Health
and Family Services
Human Development Institute,
Health and Wellness Initiative
Lexington Fire & Emergency
Services

Area of Representation

George Harrison

Dissemination of programs across
MCC; Cancer Survivor
Cancer survivors and patients

Hann Solo, Primary
Investigator

Implementation of an opioid
prevention program in the clinic

Leia Skywalker, Director

Obi Wan Kenobi, Registered
Nurse,
Ringo Starr, Director of
Therapy Operations
Fred Rogers, Social Worker

Implementation of an interventional
opioid research program in the
community
Community-based opioid treatment
referral agency; Recovering opioid
addict
External consultant for palliative
care
External consultant for long-term
rehabilitation
Social Work

Bob Ross, Program Director

Disabled population

Jason Momoa,
Fire Marshal

First Responders for Ambulatory
Services
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APPENDICES
Appendix A. DSM-IV-TR Diagnostic Categories for Substance Abuse and Substance Dependence
Type
Definition
Nonmedical use Use of prescription drugs that were not prescribed by a medical professional (i.e.,
obtained illicitly) or use for the experience or feeling a drug causes.
Misuse
Incorrect use of a medication by patients, including: use a drug for a purpose other
than that for which it was prescribed; take too little or too much of a drug; take it too
often; or take it for too long (misuse does not apply to off-label prescribing)
Abuse
A maladaptive pattern of substance use, leading to clinically significant impairment
or distress as manifested by one or more behaviorally based criteria.
Physiological
Increasing tolerance for a drug, withdrawal signs and symptoms when a drug is
dependence
discontinued, or the continued use of a substance to avoid withdrawal.
Psychological
A set of psychological symptoms that demonstrate overall loss of control or
dependence:
obsessive-compulsive drug-seeking and continued use of a substance in spite of
clearly adverse consequences. Symptoms may include specific physiological signs
of dependence such as increasing tolerance or withdrawal signs and symptoms when
the drug is discontinued.
Pseudoaddiction Drug-seeking and other behavior that is consistent with addiction but actually results
from inadequate pain relief. Once the pain is adequately treated, the person no
longer abuses the medication
Appendix B. DSM-V Diagnostic Criteria for Substance Use Disorder
1. The substance is often taken in larger amounts or over a longer period than was intended.
2. There is a persistent desire or unsuccessful effort to cut down or control use of the
substance.
3. A great deal of time is spent in activities necessary to obtain the substance, use the
substance, or recover from its effects.
4. Craving, or a strong desire or urge to use the substance, occurs.
5. Recurrent use of the substance results in a failure to fulfill major role obligations at work,
school, or home.
6. Use of the substance continues despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by the effects of its use.
7. Important social, occupational, or recreational activities are given up or reduced because
of use of the substance.
8. Use of the substance is recurrent in situations in which it is physically hazardous.
9. Use of the substance is continued despite knowledge of having a persistent or recurrent
physical or psychological problem that is likely to have been caused or exacerbated by
the substance.
10. Tolerance, as defined by either of the following:
a. A need for markedly increased amounts of the substance to achieve intoxication or
desired effect.
b. A markedly diminished effect with continued use of the same amount of the
substance.
11. Withdrawal, as manifested by either of the following:
a. The characteristic withdrawal syndrome for that substance (as specified in the DSM-5
for each substance).
b. The use of a substance (or a closely related substance) to relieve or avoid withdrawal
symptoms.
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The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSMIV-TR), provides diagnostic categories for substance abuse and substance dependence.56 There
are six definitions to consider, the program approach in this grant intends to screen for all
possible scenarios listed in Appendix A. The DSM-V replaced the separate categories of
substance abuse and substance dependence with a single category: substance use disorder
(SUD).56 The symptoms associated with an SUD fall into four major groupings: impaired
control, social impairment, risky use, and includes the pharmacological criteria of tolerance and
withdrawal. Depending on the substance, there are 10 or 11 criteria that can cause clinically
significant impairment or distress, and must occur within a 12-month period. There are three sub
classifications—mild, moderate, and severe – which are determined by the number of present
diagnostic criteria.57 Those who have two or three criteria are considered to have a “mild”
disorder, four or five is considered "moderate," and six or more symptoms, "severe." The
diagnostic criteria can be found in Appendix B.
Note that the terms ‘Tolerance’ and ‘Withdrawal’ are not used as diagnostic criteria for
persons taking opioids prescribed for clinical care. Doctors expect that patients will experience
some tolerance when placed on an opioid medication and may need an increased dosage,
especially during active cancer treatment. They also expect withdrawal effects when reducing a
pain medication, and will effectively taper down the dosage to reduce unpleasant symptoms. In
these scenarios, the patient is not considered to have developed a substance use disorder unless at
least three of the other criteria are present.56
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Appendix C. Study Design, Eligibility, and Sample Size Calculation
Study Design and Eligibility
This proposal will use a stepped-wedge study design, also known as a phased
implementation, with each clinic serving as its own control. Outcome metrics will be compared
to baseline counts during the waiting period. This design is ideal from an ethical standpoint: this
is a high-risk population and it is imperative that all eligible participants receive the intervention.
The inclusionary criteria are as broad as possible to replicate real-life scenarios. Eligible
participants will include adults aged 18 and older who score as Moderate or High risk on the
SOAPP scale. All eligible participants will be in complete remission and transitioning to a
survivorship phase, and all stages of cancer and treatment types will be included. People with
prior history of drug abuse and other pre-existing health conditions will also be included. If
interested, the participant will be enrolled in the study screening procedures. Those with a score
as moderate to high risk on the SOAPP opioid risk monitoring scale will be eligible to enroll in
the study. Upon obtaining informed consent, the participant will receive the Screening, Brief
Intervention, and Referral to Treatment intervention with motivational interviewing. Participants
will then complete the COMM survey at the 3 month, 6 month, and 12 month follow-up
appointments. More information about timeline specifications can be found in the Performance
Measures and Evaluation section. To measure whether the intervention is effective and not due
to external factors, we will compare baseline counts for the outcome measures (number of
referrals, etc.) versus post-implementation counts. Specific details on the evaluation items we
will measure can be found in the Outcome Evaluation section.
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Sample Size Calculation
According to the Markey Cancer Center 2017 Annual Report, there were a total of 619
cases for breast (all sexes), prostate, and melanoma/skin cancers treated at MCC. These break
out to 358 cases for breast, 153 cases for prostate, and 108 cases for melanoma/skin.
Effect sizes were estimated based on the literature of SBIRT, with a Cohen’s d range
from 0.17 to 1.35 within the interventional groups.58 Conventional medium effect size is
accepted at 0.5, with a large effect size accepted at 0.8. Based on the clinic volume of 619
patients treated last year for the specific disease sites, and the literature stating that 10% of
cancer survivors were still being prescribed opioids 10 years past diagnosis, our initial
assumption for the sample size would be around 100 people. To determine the appropriate
sample size, and since we knew how many patients have historically been treated at the clinic,
we conducted a sample size for percent frequency in a population as a random sample. With an
effect size of 0.8, and anticipated percent frequency of OUD 10% in the population, we found
that a sample size of 91 would be an acceptable target for recruitment. We expect to screen twice
as many people as are eligible to participate, for a total of 300 people screened.
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Appendix D. Screener and Opioid Assessment for Patients with Pain (SOAPP)® Version 1.0 14Q
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Appendix E. Current Opioid Misuse Measure (COMM)
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Appendix F. Logic Model
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Appendix G. Gantt Chart
Activity
Program Preparation,
Training and Community
Engagement
IRB Approval
Hire Key Staff
Order Supplies
Develop and test database
and surveys
Educate and Train Key Staff
and Clinic Providers
Community Advisory Group
Formation and Meetings
Program Implementation
Failure Modes and Effects
Analysis
Plan, Do, Study Act
Worksheets
Implementation in Clinic 1
(Q3, Month 7)
Implementation in Clinic 2
(Q3, Month 9)
Implementation in Clinic 3
(Q4, Month 11)
Data Collection in All 3
Clinics - includes baseline
measures
Evaluation and
Maintenance
Key Informant Interviews
Process Evaluation
Fidelity Monitoring
Outcome Evaluation

Year 1
Year 2
Year 3
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Planning
and
Readiness
Period
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Appendix H. Plan, Do, Study, Act Cycle Worksheet
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Appendix I. Organizational Chart
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BUDGET JUSTIFICATION
Primary Investigator: Hann Solo, DO, MHA, MPH; (10% / 5% / 5% FTE) Professor and Chief
of Community Medicine, Director of the Kentucky Ambulatory Network (Practice Based
Research Network). As the primary investigator of the CAIPEC grant funded by the Pfizer
Consortium and a member of the Markey Cancer Center, Dr. Solo is well-suited to be the
primary investigator of this grant. His role will include forming the Community Advisory
Group; oversee the Clinic Task Force and Practice Management Specialist; provide consultation
to clinics and act as final authority on workflow changes; review high-level progress reports of
the project to ensure milestones are being met in accordance with the funding sponsor’s
guidelines; review potential participants’ screening files and approve enrollment; assist in hiring
and termination of key staff; act as the emergency contact for Adverse Events and Serious
Adverse Events; disseminate findings to CAG, Partners, and Stakeholders.
Project Director: Jennifer M. Dolly Prothro, BA, MPH, CCRP; (100% FTE) Mrs. Dolly
Prothro has served the Markey Cancer Center in research administration for the last five years,
prior to which she served as the Project Manager for three years on the clinical research project
“Separate and combined effects of the gabapentin and THC in humans discriminating THC”
[R01 DA025605] and a clinical trial to investigate the initial safety, tolerability and efficacy of
the GABA reuptake inhibitor tiagabine to reduce cannabis use in daily cannabis users (R01
DA036550; IND#101,109; clinicaltrials.gov ID NCT01511640. Her role will be to oversee all
project staff other than the Clinic Task Force and Practice Management Specialist, monitor and
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track progress, coordinate meetings, submit IRB documentation including protocol deviations
and adverse events, and oversee dissemination of results.
Clinic Providers (3) (5% FTE each)
Clinic providers are expected to spend approximately 2 hours per week on the project. They will
will be trained in motivational interviewing, opioid prescribing guidelines, appropriate pain
management guidelines and therapies, and will be assessed per the Process Evaluation metrics.
They will deliver the intervention to participants, provide referrals, and report interactions with
each participant.
Oncology Social Worker (60% / 70% / 80%FTE)
Trains and assesses performance of providers and clinic champions in Motivational Interviewing.
Assists in patient navigation. Mediator between providers, project staff, and participants.
Behavioral Research Associates (2) (40% FTE each)
Markey’s Behavioral and Community-Based Research Shared Resource Facility hosts a team of
dedicated Behavioral Research Associates who are exceptionally well-trained in quantitative
behavioral research. Supports project implementation, screening, recruitment and tracking
efforts, provides participant payments, review all data collection and ensure procedures have
been followed according to Good Clinical Practice Guidelines, enter paper-based survey data,
conduct minor data management as needed, create participant calendar schedules, etc.
Biostatistician/Data Manager (5% FTE)
Provides support for study design, study conduct, database building, and data management.
Practice Management Specialist (5% FTE)
Finds time savings in the clinic workflow to insert research protocol.
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Clinic Task Force (2) (5% FTE each)
Maintains sustainability of protocol during project period, conducts Failure Modes and Effects
Analysis.
Consultant
$1,000 to consult on best-practices and issues as they arise in the project period.
Equipment
$5,000 to purchase two iPads for data collection, a camera to record motivational interviewing
training sessions, and three laptops for participant screening, data entry, data management,
participant recruitment, etc.
Travel
$3,000 in Year 1. $10,000 in Years 2 and 3. Provides travel funds for professional development
opportunities for project staff.
Research Incentives $6,000 for participant payments. Total of 1 screening appointment, and 3
clinic visits at $5 each. Estimated 300 participants to be screened per year.
Clinic Stipend
$20,000 to pay the clinic as an incentive to allow the study protocol to be implemented in their
clinic.
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